MRNA: financial statements from SEC — TradeAlmanac

MRNA

Moderna, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	1.94bn	3.24bn
Cost of revenue	868m	1.46bn
Research and development	3.13bn	4.54bn
Selling, general and administrative	1.02bn	1.17bn
Operating expenses	5.02bn	7.18bn
Operating income	−3.07bn	−3.95bn
Pre-tax income	−2.77bn	−3.61bn
Income tax	54m	−46m
Net income	−2.82bn	−3.56bn
Earnings per share	−7.26	−9.28
Earnings per share, diluted	−7.26	−9.28
Weighted average shares	389m	384m
Weighted average shares, diluted	389m	384m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	1.91bn	2.60bn	1.13bn	1.28bn	1.62bn	1.93bn	1.64bn	2.48bn
Receivables	71m	184m	1.05bn

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−1.87bn	−3.00bn
Share-based compensation	483m	429m
Capital expenditure	192m	1.05bn
Investing cash flow	1.95bn	1.95bn
Share buybacks	2m	0
Financing cash flow	593m	56m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)